HGF and prostate carcinoma: The findings we report here, together with the nucleolin-focused independent clinical trial underway [77,78], introduce nucleolin as an attractive target for therapeutic regulation of prostate cancer, although the details of its position in cancer cell HGF signaling remain to be found.